Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation.
Reddiconto
G
G
Chiusolo
P
P
Fiorini
A
A
Farina
G
G
Laurenti
L
L
Martini
M
M
Marchetti
S
S
Fadda
G
G
Leone
G
G
Sica
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D003937:Diagnosis, Differential; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis* / Q000635:transmission; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007231:Infant, Newborn; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000601:surgery*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000601:surgery*; D036102:Peripheral Blood Stem Cell Transplantation; D000069283:Rituximab; D014182:Transplantation, Autologous / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab